Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ascletis Pharma Inc.
歌禮製藥有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

ASCLETIS TO PRESENT STUDY RESULTS OF ORAL SMALL MOLECULE GIPR AGONIST ASC48 AND GLP-1R/GIPR/GCGR TRIPLE PEPTIDE AGONIST ASC37 AT OBESITYWEEK® 2026

– *Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37*

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces two poster presentations of its obesity assets, oral small molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37, at ObesityWeek® 2026 to be held November 14 to 17, 2026 in Washington, DC, the United States of America.

Presentation Details:

Abstract Title: Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies

Session: Preclinical Models & Emerging Obesity Therapeutics

Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

Presentation Time: November 14, 2026, 7:30 p.m.-8:30 p.m., EST

Abstract Title: ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice

Session: Preclinical Models & Emerging Obesity Therapeutics

Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

Presentation Time: November 14, 2026, 7:30 p.m.-8:30 p.m., EST

"We're excited to present the latest preclinical progress of our robust and highly differentiated obesity portfolio, including both small molecules and peptides, at ObesityWeek® 2026," said Jinzi Jason Wu, Ph.D., Founder, Chairman of the Board and chief executive officer of Ascletis, "These advancements reflect our strong determination to develop highly differentiated options to treat obesity."

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC48 and/or ASC37 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hong Kong
November 2, 2026

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.